At a glance
ClinicalIndex Comparison RecordN/ACompleted· 73 enrolled
Drug / intervention
PuraBondother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised Controlled Trial Investigating the Use of PuraBond® (3-D Matrix) in Transoral Resections of Primary Oral or Oropharyngeal Mucosal Lesions
In Brief
A clinical study evaluating PuraBond for Pain and 4 related conditions. Completed, enrolled 73 participants across 1 site.
Detailed Summary
To evaluate the use of Purabond® in transoral resections of primary oral or oropharyngeal lesions for diagnostic and therapeutic procedures. Patients will be enrolled and randomised to either have PuraBond® applied to the surgical field or not intra operatively. The primary outcome measure will assess if this intervention significantly reduces acute pain during the 30 day post-operative period alongside other post-operative complication rates and recovery outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Hemorrhage, Hemostatics, Oropharynx, Oral Cavity
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedMar 2023
Enrollment StartOct 2023
Primary CompletionAug 2024
TodayJul 2026
First PostedMar 17, 2023
Enrollment StartOct 16, 2023
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.3 years ago
Interventions
PuraBondother
Application of PuraBond to surgical field